Global DNA Synthesis Market Analysis, 2031

DNA synthesis is the production of DNA molecules with defined sequences, ranging from short oligonucleotides of a few dozen bases used as primers and probes to gene fragments, full genes, gene libraries and long constructs of tens of thousands of bases. Synthetic DNA is used in PCR and diagnostics, next-generation sequencing library preparation, gene cloning and expression, antibody and protein engineering, CRISPR guide and template design, mRNA and vaccine template production, cell and gene therapy development, synthetic biology, agricultural research and emerging DNA data storage. The dominant method is phosphoramidite chemistry, which adds bases one at a time on column or array-based platforms and becomes less efficient beyond about 200 bases, so longer sequences are assembled from shorter pieces. Enzymatic synthesis using engineered polymerases is an emerging alternative that avoids harsh chemicals and can produce longer, more complex sequences. Leading suppliers include Thermo Fisher Scientific, Integrated DNA Technologies (Danaher), Merck KGaA, GenScript, Twist Bioscience, Eurofins Genomics, Azenta (GENEWIZ), LGC Biosearch Technologies, Agilent, Ansa Biotechnologies, DNA Script, Elegen, Telesis Bio and Evonetix. Accuracy, length, turnaround time and price determine competitiveness.

Demand is driven by growth in molecular diagnostics, sequencing, biologics discovery, cell and gene therapy, mRNA medicines, synthetic biology and AI-driven protein design, which generates large numbers of sequences to test. Between 2024 and 2026, enzymatic synthesis advanced from early access to commercial products: one developer raised 35 million dollars in May 2024 to expand cell-free DNA into clinical manufacturing, another raised 54.4 million dollars in October 2025 and launched a 50 kilobase sequence-perfect clonal DNA product the same month, described as the longest commercially available, and a semiconductor-based synthesis developer opened an early access programme in 2026. Customers demanded faster turnaround and guaranteed delivery, and prices for standard gene fragments continued to fall. Sequence screening practices and customer verification became standard expectations for responsible suppliers. Challenges included error rates for long and complex sequences, manufacturing scale for clinical-grade DNA and price competition. Through 2031, key variables are enzymatic synthesis scale-up, long-DNA demand, AI-driven design volumes, genetic medicine manufacturing, pricing and responsible-use standards. Suppliers offering accurate long DNA quickly and reliably are expected to hold an advantage.

Drivers •Growth of Genetic Medicines, Biologics and Diagnostics: Cell and gene therapies, mRNA vaccines and therapeutics, antibody discovery and molecular diagnostics all depend on synthetic DNA for templates, primers, probes, constructs and libraries. Clinical development of genetic medicines requires high-quality and increasingly good manufacturing practice-grade DNA. Diagnostics and sequencing consume large volumes of oligonucleotides. Expanding pipelines sustain demand. Demand is strong.

•AI-Driven Design and Synthetic Biology: AI models for protein and gene design generate thousands of candidate sequences that must be synthesised and tested, increasing demand for gene fragments, variant libraries and fast turnaround. Synthetic biology companies engineer microbes and cell lines for chemicals, materials, food and agriculture, requiring many constructs. Automated design-build-test-learn cycles depend on reliable DNA supply. Growth is solid.

Challenges •Length, Accuracy and Complexity Limits: Chemical synthesis accumulates errors with each added base, limiting direct synthesis to short sequences, and assembling long or complex sequences with repeats, high GC content or secondary structures is difficult and slow. Sequence verification and cloning add time and cost. Some sequences fail repeatedly. Customers need long constructs for gene therapy and synthetic biology. Error correction is costly. Turnaround can suffer.



•Price Competition, Scale-Up and Responsible-Use Requirements: Prices for standard oligonucleotides and gene fragments have fallen sharply, squeezing margins, while new enzymatic platforms require large investment to reach commercial scale. Clinical-grade DNA manufacturing must meet strict quality standards. Suppliers are expected to screen orders and verify customers under industry and government guidance, adding compliance costs. Chemical waste from traditional synthesis raises environmental concerns. Competition is intense.

Trends •Commercialisation of Enzymatic and Long DNA Synthesis: Enzymatic synthesis platforms are moving to commercial products that deliver longer, sequence-perfect DNA with fewer harsh chemicals, including clonal constructs of up to 50 kilobases. Benchtop synthesisers allow laboratories to make DNA in-house. Cell-free DNA production methods aim to supply templates for genetic medicines without bacterial fermentation. Semiconductor-based approaches promise greater parallelism. Investment is flowing in. Adoption is rising.

•Faster Turnaround, Guaranteed Delivery and Integrated Services: Suppliers are competing on speed, offering guaranteed delivery times, refunds for late orders and rapid services for complex sequences. Integrated offerings combine synthesis with cloning, sequencing verification, variant libraries and protein expression. Online ordering platforms check manufacturability and screen sequences automatically. Large customers sign volume agreements. Service models are evolving. Interest is growing.

Oligonucleotide synthesis leads because primers, probes and guides are used in very large volumes, while gene synthesis grows fastest with genetic medicines and AI-driven design. Oligonucleotide synthesis is the largest product segment because short DNA sequences, including PCR primers, probes, sequencing adapters, CRISPR guide templates, hybridisation capture baits and antisense research molecules, are used in very large volumes across research, diagnostics and sequencing laboratories. Oligonucleotides are produced on high-throughput column and array platforms and sold at low unit prices, but volumes are enormous. Array-synthesised oligonucleotide pools support library construction and target enrichment for sequencing. Gene synthesis, including gene fragments, full genes, codon-optimised constructs, variant libraries and clonal DNA, is the fastest growing segment because antibody and protein engineering, AI-driven design, cell and gene therapy development, mRNA template production and synthetic biology all require custom genes, often in large numbers and with fast turnaround. Long DNA constructs of tens of kilobases are a growing niche for gene therapy vectors, pathway engineering and genome projects, supported by new enzymatic platforms. Clinical-grade and good manufacturing practice DNA for therapeutic manufacturing commands premium prices. Quality documentation requirements are correspondingly strict. Through the forecast period, oligonucleotides are expected to remain the largest segment by volume, while gene synthesis and long DNA grow fastest by value as genetic medicine pipelines and AI-driven design programmes expand across pharmaceutical, academic and industrial research.


Chemical phosphoramidite synthesis leads because it is mature and scalable, while enzymatic synthesis grows fastest through longer, cleaner and more complex sequences. Chemical synthesis using phosphoramidite chemistry is the largest technology segment because it is mature, well understood and highly scalable, and it underpins nearly all commercial oligonucleotide and gene fragment production on column, plate and silicon array platforms. Silicon-based array synthesis allows very large numbers of oligonucleotides to be made in parallel at low cost, supporting gene synthesis and library construction. However, chemical synthesis accumulates errors with length, uses hazardous solvents and generates chemical waste. Enzymatic synthesis, using engineered terminal deoxynucleotidyl transferase or other polymerases, is the fastest growing technology because it works in water-based conditions, can produce longer and more complex sequences and has reached commercial launch with products such as long clonal constructs and benchtop synthesisers. Cell-free amplification methods produce large quantities of DNA templates for genetic medicines without bacterial culture. Semiconductor and microfluidic platforms aim to increase parallelism and reduce cost. Assembly methods, error correction and sequence verification remain essential in all workflows. Many providers combine several technologies within one facility. Through the forecast period, chemical synthesis is expected to remain the largest segment, while enzymatic and cell-free methods grow fastest as they scale up and as customers demand longer sequences with fewer errors and lower environmental impact.


Research and development applications lead because discovery work consumes most custom DNA, while therapeutics and diagnostics grow fastest with genetic medicines and molecular testing. Research and development is the largest application segment because academic, pharmaceutical and biotechnology laboratories use synthetic DNA for cloning, gene expression, protein engineering, functional genomics, CRISPR studies, antibody discovery and synthetic biology, and AI-driven design is increasing the number of sequences tested. Variant libraries and pooled oligonucleotides support high-throughput screening. Therapeutics is the fastest growing application because cell and gene therapies, mRNA vaccines and therapeutics, DNA vaccines and other genetic medicines require synthetic DNA for templates, vectors and editing components, and clinical programmes need high-quality and good manufacturing practice-grade material. Diagnostics is a large and growing application, using primers and probes in PCR tests, sequencing-based tests, oncology panels and infectious disease assays. Agriculture and food applications use synthetic DNA for crop and livestock research and testing. DNA data storage is an emerging application that could require very large volumes of low-cost synthesis if costs fall sufficiently. Training uses are smaller but steady. Each application has different requirements for length, accuracy, quantity, documentation and turnaround time. Through the forecast period, research and development is expected to remain the largest segment, while therapeutics and diagnostics grow fastest as genetic medicines advance through clinical development and as molecular testing expands in clinical practice.


Pharmaceutical and biotechnology companies lead because discovery and genetic medicine programmes consume most synthetic DNA, while diagnostic and synthetic biology companies grow quickly. Pharmaceutical and biotechnology companies are the largest end-user group because they use synthetic DNA extensively in antibody and protein discovery, target validation, cell line engineering, gene therapy and mRNA development and manufacturing, and they often sign volume agreements with suppliers for gene fragments, libraries and clinical-grade templates. Academic and research institutes are a large group, using synthetic DNA for basic research, genomics and method development, although spending depends on research funding. Contract research organisations use synthetic DNA when performing discovery and testing for clients and are growing as outsourcing increases. Diagnostic companies and clinical laboratories buy large volumes of primers and probes for test kits and laboratory-developed tests. Synthetic biology and industrial biotechnology companies are a fast-growing group, engineering organisms to produce chemicals, materials, food ingredients and agricultural products, requiring many constructs and pathways. Agricultural companies use synthetic DNA in breeding and trait development. Large customers often sign multi-year supply agreements covering pricing, turnaround commitments and quality standards, while smaller laboratories order online. Through the forecast period, pharmaceutical and biotechnology companies are expected to remain the largest users, while synthetic biology, diagnostics and contract research organisations grow fastest as design-driven biology spreads across industries and as testing volumes rise worldwide.


North America is the leading region, home to major suppliers such as Integrated DNA Technologies, Thermo Fisher Scientific and Twist Bioscience and to many enzymatic synthesis developers, including Ansa Biotechnologies, which raised 54.4 million dollars in October 2025 and launched a 50 kilobase sequence-perfect clonal DNA product, and Elegen, which raised 35 million dollars in May 2024 to expand cell-free DNA into clinical manufacturing. Large pharmaceutical, gene therapy, mRNA and synthetic biology sectors drive demand. Industry and government guidance on screening synthetic DNA orders shapes supplier practices. By 2031, growth is expected from genetic medicines, AI-driven design and long DNA.

Europe is a major region with strong academic research, pharmaceutical companies and suppliers such as Merck KGaA, Eurofins Genomics and LGC. France is home to DNA Script, an enzymatic synthesis company, and the United Kingdom to Evonetix, which opened an early access programme for semiconductor-synthesised DNA in 2026. Genetic medicine development and diagnostics drive demand. Environmental expectations favour cleaner synthesis methods. By 2031, growth is expected from enzymatic synthesis, genetic medicines and diagnostics.

Asia-Pacific is the fastest growing region. China is home to large gene synthesis providers, including GenScript, which serve global customers at competitive prices, and its biotechnology sector is growing rapidly. Japan and South Korea have strong research and diagnostics markets. Singapore and Australia invest in synthetic biology. India's contract research sector uses synthetic DNA. By 2031, the region is expected to show the highest growth.

Latin America is a growing region where synthetic DNA is used in academic research, diagnostics and agricultural biotechnology in Brazil, Argentina and Mexico, mainly supplied by international providers. Barriers include import times and costs. By 2031, growth is expected from diagnostics and agricultural research.

The Middle East and Africa are developing regions. Israel has a strong biotechnology sector, Gulf countries are investing in genomics and biotechnology, and African laboratories use primers and probes for infectious disease diagnostics. By 2031, growth is expected from Gulf genomics and diagnostics.

April 2026: Evonetix opens early access programme for semiconductor-synthesised DNA: Researchers can apply to receive DNA made on the company's chip-based platform and test it in routine molecular biology workflows ahead of full commercialisation.

October 2025: Ansa Biotechnologies launches 50 kilobase clonal DNA product: The enzymatic synthesis company introduced what it described as the longest sequence-perfect synthetic DNA commercially available, delivered in 25 days or less.

October 2025: Ansa Biotechnologies raises 54.4 million dollars in Series B financing: The funding supports scale-up of enzymatic DNA synthesis, with an on-time delivery guarantee and US-based manufacturing.

May 2024: Elegen raises 35 million dollars in Series B financing: The cell-free DNA company raised funds to expand its ENFINIA DNA product line into clinical workflows, including GMP-compliant DNA for genetic medicines.


Considered in this report
• Historic Year: 2020
• Base Year: 2025
• Estimated Year: 2026
• Forecast Year: 2031

Aspects covered in this report
• Global DNA Synthesis Market with its segments and regional outlook
• Various drivers and challenges
• Ongoing trends and developments
• Key developments and regulatory milestones

By Product
• Oligonucleotide synthesis
• Gene synthesis
• Long DNA constructs
• Clinical-grade DNA

By Technology
• Chemical phosphoramidite synthesis
• Enzymatic synthesis
• Cell-free DNA production
• Semiconductor and other platforms

By Application
• Research and development
• Therapeutics
• Diagnostics
• Agriculture and food
• DNA data storage

By End User
• Pharmaceutical and biotechnology companies
• Academic and research institutes
• Contract research organisations
• Diagnostic companies and laboratories
• Synthetic biology companies